Please login to the form below
Focus on multiple myeloma treatment: Witnessing a transformation
Consultant David Cooney of Blue Latitude Health will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
I get very excited by science,
specifically pharmacology, and when I was studying drug development I used to
read case studies about the impact ground-breaking drugs had, and imagine what
it must have been like to be part of that success. I used to harass an old mentor
of mine who was involved in the Herceptin launch for stories about introducing
such an innovative treatment, hoping one day I’d get a chance to be part of such
a transformation in care.
I'm now part of a team at Blue Latitude Health working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
If we reflect on what the treatment options were 10 years ago, two drugs stand out – melphalan and thalidomide. Melphalan, a distant cousin of the mustard gas used to kill World War I soldiers, and thalidomide, the infamous chiral drug which caused birth defects in the 1960s. These drugs have been shown to be efficacious options for patients with MM, but with a low therapeutic index. This meant significant cost in terms of toxicity, and marginal impact on the overall survival of patients.
![]()
I'm now part of a team at Blue Latitude Health working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, I will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
The Therapeutic Index of multiple myeloma therapies
“It is easy to be overwhelmed by hype in cancer research, with promising new discoveries often portrayed as so-called game changers….but myeloma is a rare exception” [sic] was the opening of a recent editorial in the Lancet on multiple myeloma. To appreciate the context of this statement we need to consider what treatment options were like for myeloma patients in the past.If we reflect on what the treatment options were 10 years ago, two drugs stand out – melphalan and thalidomide. Melphalan, a distant cousin of the mustard gas used to kill World War I soldiers, and thalidomide, the infamous chiral drug which caused birth defects in the 1960s. These drugs have been shown to be efficacious options for patients with MM, but with a low therapeutic index. This meant significant cost in terms of toxicity, and marginal impact on the overall survival of patients.
Download the full article from Blue Latitude Health
Company Details
Blue Latitude Health
+44 203 328 1840
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Q&A with Dr Timothy Vollmer, leading MS Neurologist
- Blue Latitude Health sits down with key opinion leader and specialist neurologist Dr Timothy Vollmer to better understand the paradigm shift in MS treatment. He explains the challenges neurologists face when making treatment decisions, and why patients need to be treated with more efficacious drugs earlier on.
Blue Latitude Health
- Living my best life with multiple sclerosis
- Multi-award-winning advocate and patient engagement champion Trishna Bharadia gives a valuable insight into life with multiple sclerosis. She explains how treatment has changed, how our healthcare systems and pharma can unite to improve quality of life for MS patients today, and why her diagnosis isn’t stopping her achieving her goals.
Blue Latitude Health
- Creative review: ESMO 2018
- BLH reviews the creative concepts exhibited at the European Society for Medical Oncology (ESMO) 2018 Congress, crowning our best booth winners and giving key insights on how to develop an inspiring design for your booth.
Blue Latitude Health
- A unique tool for turning data into brand strategy
- Head of Insight Martine Leroy, uses her 25+ years’ experience to develop an exclusive perceptual framework for research design and analysis, which generates a deeper understanding of customer needs and the changing market dynamics
Blue Latitude Health
- Positive disruption: getting to the bottom of big data
- BLH speaks to Nicole Huyghe, founder and Managing Director of data science consultancy Boobook, about the growing need from businesses for data-driven decision making.
Blue Latitude Health
- We've moved!
- Blue Latitude Health has moved office to a new location in Barbican, Central London, following a year of substantial growth.
Blue Latitude Health
- About us
- Contact us
- How to advertise
- Site map
- All content copyright © PMGroup Worldwide Ltd 2019
